During October 2025, Clover Biopharmaceuticals (02197) did not alter its authorized share capital, which remains at 2,000,000,000 ordinary shares with a par value of USD 0.0001 each, totaling USD 200,000.

As of the end of October 2025, the total issued shares increased by 386,000 to 1,297,780,179. This change primarily reflects the exercise of share options under the Pre-IPO Share Option Plan and the Post-IPO Share Option Plan. A total of 28,000 new shares were issued through the Pre-IPO Share Option Plan, while 358,000 new shares were issued under the Post-IPO Share Option Plan. The exercise of these options generated HKD 3,088 in total proceeds.